New concepts for relapsed Hodgkin's disease

Annals of Oncology

Volumn 13, Issue SUPPL. 1, 2002, Pages 117-121

  Josting, A ^a,b   Raemakers, J M ^c   Diehl, V ^a,b   Engert, A ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b German Hodgkin Lymphoma Study Group   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; VINCRISTINE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; FORECASTING; PATHOLOGY; REVIEW; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; FORECASTING; HODGKIN DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0036265411     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/13.S1.117     Document Type: Article

References (31)

1. Hodgkin's disease. Prognostic factors and treatment startegies
2. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy
3. Salvage chemotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP
4. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM)
5. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patients
6. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy
7. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease
8. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation
9. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
10. HDR-1: High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): Final results of a randomized GHSG and EBMT trial (HD-R1)
11. High-dose sequential chemoradiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease-a 6-year update
12. Five-year update of the Milan Cancer Institute randomized trial of high-dose sequential (HDS) vs MACOPB therapy for diffuse large-cell lymphomas
13. Four-step high-dose sequential chemotherapy with double hematopoetic progenitor-cell rescue for metastatic breast cancer
14. Sequential cycles of high-dose carboplatin administered with recombinat human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and delivering multiple courses of dose-intensive therapy
15. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma
16. High-dose sequential chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma
17. The Norton-Simon hypothesis revisited
18. Cologne high dose sequential chemotherapy in relapsed and refractory Hodgkin's and aggressive non-Hodgkin's lymphoma-results of a multicenter phase-II study
19. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience
20. Allogeneic marrow transplantation for refractory Hodgkin's disease
21. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease
22. Allogeneic bone marrow transplantation is not better than autologous transplant for patients with relapsed Hodgkin's disease
23. Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease
24. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
25. A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GvHD, disease control and potential for GvL with adoptive immunotherapy
26. Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease
27. Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study
28. A phase I study of an anti-CD25 ricin A chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma
29. A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30 positive Hodgkin's and non-Hodgkin's lymphoma
30. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody
31. Current strategies of antibody-based tretment in Hodgkin's disease